Literature DB >> 17955492

New trends in the treatment of bone metastasis.

Evan T Keller1, Jinlu Dai, June Escara-Wilke, Christopher L Hall, Kathleen Ignatoski, Russell S Taichman, Jill Keller.   

Abstract

Bone metastasis is often the penultimate harbinger of death for many cancer patients. Bone metastases are often associated with fractures and severe pain resulting in decreased quality of life. Accordingly, effective therapies to inhibit the development or progression of bone metastases will have important clinical benefits. To achieve this goal understanding the mechanisms through which bone metastases develop and progress may provide targets to inhibit the metastases. In the past few years, there have been advances in both understanding the mechanisms through which bone metastases develop and how they impact bone remodeling. Additionally, gains in promising clinical strategies to target bone metastases have been developed. In this prospectus, we will discuss some of these advances. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17955492     DOI: 10.1002/jcb.21540

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

1.  Disseminated prostate cancer cells can instruct hematopoietic stem and progenitor cells to regulate bone phenotype.

Authors:  Jeena Joseph; Yusuke Shiozawa; Younghun Jung; Jin Koo Kim; Elisabeth Pedersen; Anjali Mishra; Janet Linn Zalucha; Jingcheng Wang; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

2.  Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease.

Authors:  Xu Feng
Journal:  Curr Chem Biol       Date:  2009-05-01

3.  Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.

Authors:  Kosuke Mizutani; Sudha Sud; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2009-03-01       Impact factor: 4.429

4.  αvβ6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor.

Authors:  Huimin Lu; Tao Wang; Jing Li; Carmine Fedele; Qin Liu; Jianzhong Zhang; Zhong Jiang; Dhanpat Jain; Renato V Iozzo; Shelia M Violette; Paul H Weinreb; Roger J Davis; Daniel Gioeli; Thomas J FitzGerald; Dario C Altieri; Lucia R Languino
Journal:  Cancer Res       Date:  2016-07-22       Impact factor: 12.701

5.  Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer.

Authors:  Moammir H Aziz; Nancy E Dreckschmidt; Ajit K Verma
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 6.  Novel targets with potential therapeutic applications in osteosarcoma.

Authors:  Chand Khanna
Journal:  Curr Oncol Rep       Date:  2008-07       Impact factor: 5.075

7.  Neural progenitor cell-mediated delivery of osteoprotegerin limits disease progression in a preclinical model of neuroblastoma bone metastasis.

Authors:  Thomas L Sims; J Blair Hamner; Rebecca A Bush; Peter E Fischer; Seung U Kim; Karen S Aboody; Beth McCarville; Mary K Danks; Andrew M Davidoff
Journal:  J Pediatr Surg       Date:  2009-01       Impact factor: 2.545

8.  Monocyte chemotactic protein 1 promotes lung cancer-induced bone resorptive lesions in vivo.

Authors:  Zhong Cai; Qiuyan Chen; Jun Chen; Yi Lu; Guozhi Xiao; Zhihao Wu; Qinghua Zhou; Jian Zhang
Journal:  Neoplasia       Date:  2009-03       Impact factor: 5.715

9.  Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.

Authors:  Francesco Crea; Elaine M Hurt; Lesley A Mathews; Stephanie M Cabarcas; Lei Sun; Victor E Marquez; Romano Danesi; William L Farrar
Journal:  Mol Cancer       Date:  2011-04-18       Impact factor: 27.401

10.  Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.

Authors:  Wei Chen; Yi Liu; Hongde Chen; Hao Ning; Kejia Ding
Journal:  Int J Oncol       Date:  2017-06-12       Impact factor: 5.650

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.